Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$305.2 million.

  • Revolution Medicines' Income from Continuing Operations fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 69.46%. This contributed to the annual value of -$600.0 million for FY2024, which is 37.51% down from last year.
  • Revolution Medicines' Income from Continuing Operations amounted to -$305.2 million in Q3 2025, which was down 23.17% from -$247.8 million recorded in Q2 2025.
  • Revolution Medicines' Income from Continuing Operations' 5-year high stood at -$37.2 million during Q1 2021, with a 5-year trough of -$305.2 million in Q3 2025.
  • Its 3-year average for Income from Continuing Operations is -$163.9 million, with a median of -$156.3 million in 2024.
  • Data for Revolution Medicines' Income from Continuing Operations shows a maximum YoY tumbled of 185.87% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Revolution Medicines' Income from Continuing Operations stood at -$52.7 million in 2021, then decreased by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then decreased by 20.42% to -$194.5 million in 2024, then slumped by 95.28% to -$305.2 million in 2025.
  • Its Income from Continuing Operations stands at -$305.2 million for Q3 2025, versus -$247.8 million for Q2 2025 and -$213.4 million for Q1 2025.